Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Nov 27, 2024; 16(11): 3400-3407
Published online Nov 27, 2024. doi: 10.4240/wjgs.v16.i11.3400
Benefits and drawbacks of radiofrequency ablation via percutaneous or minimally invasive surgery for treating hepatocellular carcinoma
Ching-Lung Hsieh, Cheng-Ming Peng, Chun-Wen Chen, Chang-Hsien Liu, Chih-Tao Teng, Yi-Jui Liu
Ching-Lung Hsieh, Department of Computer Science and Information Engineering, Feng Chia University, Taichung 40724, Taiwan
Ching-Lung Hsieh, Cheng-Ming Peng, Department of Surgery, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
Cheng-Ming Peng, School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
Chun-Wen Chen, Department of Radiology, Taichung Armed Forces General Hospital, Taichung 406, Taiwan
Chun-Wen Chen, Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung 406, Taiwan
Chun-Wen Chen, Department of Radiology, School of Medicine, National Defense Medical Center, Taipei 11490, Taiwan
Chang-Hsien Liu, Department of Medical Imaging, China Medical University Hsinchu Hospital and China Medical University, Hsinchu 302, Taiwan
Chang-Hsien Liu, Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu 300, Taiwan
Chih-Tao Teng, Department of Radiology, Nantou Hospital of the Ministry of Health and Welfare, Nantou 540, Taiwan
Chih-Tao Teng, Master’s Program of Biomedical Informatics and Biomedical Engineering, Feng Chia University, Taichung 407, Taiwan
Yi-Jui Liu, Department of Automatic Control Engineering, Feng Chia University, Taichung 407, Taiwan
Author contributions: Hsieh CL and Peng CM provided expertise and experience in minimally invasive surgery-radiofrequency ablation; Chen CW, Liu CH, and Teng CT contributed expertise in percutaneous-radiofrequency ablation; Liu YJ conducted a survey and reviewed relevant studies; Hsieh CL and Liu YJ drafted the manuscript; All authors have reviewed and approved the final version of the manuscript.
Supported by Feng Chia University/Chung Shan Medical University, No. FCU/CSMU 112-001 (to Peng CM and Liu YJ); Taiwan National Science and Technology Council, No. 111-2314-B-035-001-MY3; and Taichung Armed Forces General Hospital, No. 107A42.
Conflict-of-interest statement: Compal Electronics supported a minor portion to Cheng-Ming Peng and Yi-Jui Liu. The company had no role in the editorial design, data interpretation, or manuscript preparation. No additional personal fees or non-financial support were received. The other authors have no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yi-Jui Liu, PhD, Professor, Department of Automatic Control Engineering, Feng Chia University, No. 100 Wenhwa Road, Seatwen, Taichung 407, Taiwan. erliu@fcu.edu.tw
Received: June 3, 2024
Revised: June 29, 2024
Accepted: July 18, 2024
Published online: November 27, 2024
Processing time: 149 Days and 3.4 Hours
Core Tip

Core Tip: This article reviews the role of liver resection and radiofrequency ablation (RFA) in the treatment of early-stage hepatocellular carcinoma (HCC), comparing their pros and cons and proposing a potential trajectory involving the combination of surgical resection and RFA in future therapy. Despite percutaneous RFA's advantages, its high recurrence rate compared to resection remains a challenge. Techniques like artificial ascites and imaging enhancements aim to improve percutaneous RFA's efficacy and reduce recurrence. Minimally invasive surgery with intraoperative RFA (MIS-IORFA) enhances RFA's precision and safety. Applying these refined techniques to MIS-IORFA could yield long-term benefits in HCC management.